- Takeda Canada and the CIHR Institute of Genetics have partnered to establish a fellowship program to identify emerging talent and innovation to support advances in the field of rare diseases across Canada.
- The scholarship program will provide $720,000 to support four (4) research grants.
- Opportunity for postdoctoral fellows to accelerate rare disease research through dedicated funding.
TORONTO, September 7, 2022 /CNW/ – Takeda Canada Inc. (“Takeda”) is proud to announce a rare disease research grant in partnership with the Canadian Institutes of Health Research (CIHR). The fellowship will provide support and training to ensure participants become scientific, professional, or organizational leaders within and beyond the health research enterprise. This specific opportunity aims to support postdoctoral fellows focused on one or more rare disease disorders. A full list of rare disease research areas is available online at Researchnet-recherchenet.ca.
“Research on rare diseases is a priority in Canada. With advances in genetics and genomics, we have the ability to ensure that rare diseases are diagnosed and managed more efficiently and effectively, and we aspire to see this integrated into the delivery of health care in Canada.” , said Dr. Christophe McMaster, Scientific Director of the CIHR Institute of Genetics. “We are delighted to partner with Takeda on this grant and look forward to supporting world-class Canadian talent in genetic research.
Takeda and CIHR invest $720,000 to fund up to four (4) scholarships for a maximum of three (3) years. Takeda and the CIHR Institute of Genetics contributed $360,000 each to fund this priority area, a leading example of optimal public-private partnerships to support innovative and priority research in Canada. Scholarship applications will be accepted until October 5, 2022.
Interested postdoctoral fellows are encouraged to review the specific requirements here.
“Partnerships are imperative to supporting research discovery and improving patient care in our health care system,” said Dr. Jefferson tea, Vice President, Medical and Scientific Affairs, Takeda, Canada. “The Takeda and CIHR Institute of Genetics Fellowship will support innovation and advances in the treatment of rare diseases while fostering future collaboration.
About the impact of rare diseases in Canada
A “rare” disease is a disease that affects a very small number of individuals. It is often genetic, chronic throughout a patient’s life, and potentially fatal.I In Canada, one in 12 Canadians is affected by a rare disease.ii
About the Canadian Institutes of Health Research
At the Canadian Institutes of Health Research (CIHR), we know that research has the power to change lives. As Canada’s health research investment agency, we work with partners and researchers to support discoveries and innovations that improve our health and strengthen our health care system.
About Takeda Canada Inc.
Takeda Canada Inc. is the Canadian organization of Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK), a global leader in values-based biopharmaceutical research and development, headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our employees and the planet. Takeda focuses its R&D efforts on four therapeutic areas: oncology, rare genetics and hematology, neurosciences and gastroenterology (GI). We also make targeted R&D investments in plasma-derived therapies and vaccines. We are focused on developing highly innovative medicines that help make a difference in people’s lives by pushing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust pipeline and diversified in terms of modalities. Our employees are committed to improving the quality of life of patients and working with our healthcare partners in approximately 80 countries and regions. For more information, visit: takeda.com/en-ca
SOURCETakeda Canada Inc.
Show original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/07/c1002.html